[SCHEDULE 13G] Electra Therapeutics, Inc. Passive Investment Disclosure (>5%)
Electra Therapeutics: LSP 7 reports 6% stake
The ownership report assigns shared voting and disposition power to the reporting entities, while named managing directors disclaim beneficial ownership.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Electra Therapeutics, Inc. (ETRA) is the issuer of common stock for which LSP 7 Cooperatief U.A. and LSP 7 Management B.V. report beneficial ownership of 3,795,281 shares, or 6.0%, as of September 21, 2026. The reported position is based on 62,766,955 common shares outstanding as of that date. LSP 7 is the record holder, and LSP 7 Management B.V. is LSP 7’s sole director; both report shared voting and dispositive power over the shares. Managing directors Merijn Klaassen, Rene Kuijten and Joachim Rothe may also be deemed beneficial owners, and each disclaims beneficial ownership.
Key Figures
Beneficially owned shares:3,795,281 sharesPercent of class:6.0%Common shares outstanding:62,766,955 shares+2 more
5 metrics
Beneficially owned shares3,795,281 sharesAs of September 21, 2026
Percent of class6.0%As of September 21, 2026
Common shares outstanding62,766,955 sharesAs of September 21, 2026
Shared voting power3,795,281 sharesReported by each reporting person
Shared dispositive power3,795,281 sharesReported by each reporting person
Key Terms
beneficial ownership, shared voting power, shared dispositive power, record holder
4 terms
beneficial ownershipregulatory
"represents beneficial ownership of Common Stock of the Issuer"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerregulatory
"Shared Voting Power 3,795,281"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared Dispositive Power 3,795,281"
record holderregulatory
"LSP 7 is the record holder of the shares reported herein"
A record holder is the person or institution officially listed in a company’s books as the owner of shares, bonds or other securities on a specific date. Think of it like the name on the registration of a car: being the record holder determines who is eligible for dividends, voting at meetings, or other shareholder rights. Investors care because actions tied to a set date apply only to those recorded as owners.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ETRA shares do the reporting persons beneficially own?
LSP 7 Cooperatief U.A. and LSP 7 Management B.V. report beneficial ownership of 3,795,281 Electra Therapeutics common shares, equal to 6.0% as of September 21, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Electra Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
284825106
(CUSIP Number)
09/21/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
284825106
1
Names of Reporting Persons
LSP 7 Cooperatief U.A.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,795,281.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,795,281.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,795,281.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
284825106
1
Names of Reporting Persons
LSP 7 Management B.V.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,795,281.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,795,281.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,795,281.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Electra Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
230 E Grand Avenue, Suite S-100, South San Francisco, California 94080.
Item 2.
(a)
Name of person filing:
Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:
LSP 7 Cooperatief U.A. ("LSP 7"); and
LSP 7 Management B.V.
(b)
Address or principal business office or, if none, residence:
The principal business address of each of the Reporting Persons is c/o EQT Life Sciences, Johannes Vermeerplein 9, 1071 DV Amsterdam, the Netherlands.
(c)
Citizenship:
Each of the Reporting Persons is organized under the laws of the Netherlands.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
284825106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of September 21, 2026, based on 62,766,955 shares of Common Stock outstanding as of September 21, 2026, as disclosed in the Issuer's prospectus supplement on Form 424B4 filed on September 18, 2026.
LSP 7 is the record holder of the shares reported herein.
LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Merijn Klaassen, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Merijn Klaassen, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the shares of Common Stock held of record by LSP 7. Each of these individuals disclaims beneficial ownership of such shares.
(b)
Percent of class:
6.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
3,795,281
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
3,795,281
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
